Notice: This company has been marked as potentially delisted and may not be actively trading. Flex Pharma (FLKS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends FLKS vs. MNPR, TLSA, COYA, IMUX, AVTX, ADAG, MIST, ANIX, MNOV, and KPTIShould you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Monopar Therapeutics (MNPR), Tiziana Life Sciences (TLSA), Coya Therapeutics (COYA), Immunic (IMUX), Avalo Therapeutics (AVTX), Adagene (ADAG), Milestone Pharmaceuticals (MIST), Anixa Biosciences (ANIX), MediciNova (MNOV), and Karyopharm Therapeutics (KPTI). These companies are all part of the "medical" sector. Flex Pharma vs. Monopar Therapeutics Tiziana Life Sciences Coya Therapeutics Immunic Avalo Therapeutics Adagene Milestone Pharmaceuticals Anixa Biosciences MediciNova Karyopharm Therapeutics Monopar Therapeutics (NASDAQ:MNPR) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is MNPR or FLKS more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. Flex Pharma's return on equity of -98.04% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -107.21% -87.57% Flex Pharma -1,208.42%-98.04%-83.37% Which has higher valuation and earnings, MNPR or FLKS? Monopar Therapeutics has higher earnings, but lower revenue than Flex Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$8.40M-$1.97-10.01Flex Pharma$840K31.41-$21.92MN/AN/A Do insiders & institutionals believe in MNPR or FLKS? 1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 14.4% of Flex Pharma shares are held by institutional investors. 34.9% of Monopar Therapeutics shares are held by company insiders. Comparatively, 7.6% of Flex Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to MNPR or FLKS? In the previous week, Monopar Therapeutics had 5 more articles in the media than Flex Pharma. MarketBeat recorded 5 mentions for Monopar Therapeutics and 0 mentions for Flex Pharma. Monopar Therapeutics' average media sentiment score of 1.00 beat Flex Pharma's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Monopar Therapeutics Positive Flex Pharma Neutral Does the MarketBeat Community prefer MNPR or FLKS? Flex Pharma received 319 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. Likewise, 73.23% of users gave Flex Pharma an outperform vote while only 72.41% of users gave Monopar Therapeutics an outperform vote. CompanyUnderperformOutperformMonopar TherapeuticsOutperform Votes4272.41% Underperform Votes1627.59% Flex PharmaOutperform Votes36173.23% Underperform Votes13226.77% Do analysts prefer MNPR or FLKS? Monopar Therapeutics currently has a consensus target price of $27.33, indicating a potential upside of 38.68%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Monopar Therapeutics is more favorable than Flex Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Flex Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, MNPR or FLKS? Monopar Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Flex Pharma has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. SummaryMonopar Therapeutics beats Flex Pharma on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Flex Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLKS vs. The Competition Export to ExcelMetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.38M$6.58B$5.14B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E RatioN/A10.93132.3717.61Price / Sales31.41363.851,231.9986.52Price / CashN/A52.5940.0636.27Price / Book2.8610.176.956.36Net Income-$21.92M$153.36M$119.48M$226.00M Flex Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLKSFlex PharmaN/A$1.46+4.3%N/A+104.3%$26.38M$840,000.000.004Gap UpMNPRMonopar Therapeutics3.6035 of 5 stars$19.71+3.7%$27.33+38.7%+1,213.5%$104.07MN/A-10.0110TLSATiziana Life Sciences0.5447 of 5 stars$0.97-3.0%N/A+75.4%$102.24MN/A0.008Positive NewsCOYACoya Therapeutics3.0604 of 5 stars$6.08+0.8%$16.67+174.1%+10.6%$101.60M$6M-9.356IMUXImmunic3.1511 of 5 stars$1.12+3.7%$12.25+998.7%-3.6%$100.44MN/A-0.9170Positive NewsAVTXAvalo Therapeutics2.1387 of 5 stars$9.65-11.5%N/A-47.4%$100.26M$1.92M0.0040Positive NewsADAGAdagene2.9171 of 5 stars$2.26+8.1%$5.00+121.2%+52.6%$100.05M$18.11M0.00260News CoveragePositive NewsGap UpMISTMilestone Pharmaceuticals2.3878 of 5 stars$1.85-0.5%$12.00+548.6%-18.4%$98.66M$1M-2.3030ANIXAnixa Biosciences2.8761 of 5 stars$3.06+0.7%$7.00+128.8%+2.9%$98.47M$210,000.00-7.855Analyst ForecastNews CoverageMNOVMediciNova0.6718 of 5 stars$2.00+2.6%N/A-5.3%$98.10M$1M-9.2910News CoverageKPTIKaryopharm Therapeutics3.9684 of 5 stars$0.77-1.3%$5.00+550.2%-1.5%$97.12M$148.44M-0.67380 Related Companies and Tools Related Companies Monopar Therapeutics Competitors Tiziana Life Sciences Competitors Coya Therapeutics Competitors Immunic Competitors Avalo Therapeutics Competitors Adagene Competitors Milestone Pharmaceuticals Competitors Anixa Biosciences Competitors MediciNova Competitors Karyopharm Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FLKS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Flex Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
